surely the better question: is there any benefit to be gained for travere doing a trial combining sparsentan with a drug with such a feeble efficacy profile.
remember:
>>>a woefully inadequate 17% proteinuria drop in FSGS in probably one of the smallest phase 2 anybody has ever conducted
>>>zero effect in diabetes (yes zero)
>>> Ccr2 inhibition a known failed mechanism in kidney disease
all adds up to my predicted 65-75% probability of failure for d200
Denigrate sparsentan at your peril!!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.035(6.25%) |
Mkt cap ! $308.6M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 57.0¢ | 52.0¢ | $1.033M | 1.931M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18732 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 30517 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| DXB (ASX) Chart |